221148-26-1

Basic information

• Product Name: 2-Propynoicacid,3-(4-ethoxyphenyl)-,methylester(9CI)
• Synonyms: 2-Propynoicacid,3-(4-ethoxyphenyl)-,methylester(9CI)
• CAS NO: 221148-26-1
• Molecular Formula: C₁₂H₁₂O₃
• Molecular Weight: 0
• Product Categories: ETHOXY
• Mol File: 221148-26-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Propynoicacid,3-(4-ethoxyphenyl)-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propynoicacid,3-(4-ethoxyphenyl)-,methylester(9CI)(221148-26-1)
• EPA Substance Registry System: 2-Propynoicacid,3-(4-ethoxyphenyl)-,methylester(9CI)(221148-26-1)

Safety Data

• Hazardous Substances Data: 221148-26-1(Hazardous Substances Data)

Upstream product

• 558-13-4 carbon tetrabromide 
• 10031-82-0 4-ethoxybenzaldehyde 
• 79-22-1 methyl chloroformate 
• 79887-14-2 4-ethoxyphenylacetylene 

Downstream Products

• 1123725-59-6 dimethyl 3-(4-ethoxyphenyl)-1H-pyrole-2,4-dicarboxylate 
• 221148-34-1 2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester 

Relevant articles and documents

Enantioselective Fluorination of α-Branched β-Ynone Esters Using a Cinchona-Based Phase-Transfer Catalyst

Herein, we report the fluorination of α-branched β-ynone esters to afford their corresponding quaternary fluorinated products with good enantioselectivity (ee = 73-90%) using a cinchona-based phase-transfer catalyst. α-Branched β-ynone esters possess a highly acidic α-proton and form their corresponding enolate as a single isomer, which allows the enantioselective fluorination reaction to occur under standard cinchona-based phase-transfer catalyst conditions. Moreover, the obtained α-fluorinated product can be treated with [(SPhos)AuNTf2] (1 mol %) to afford a fluorinated 3,5-diketo carboxylic acid.

FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTANTS

The present invention relates to formylated xanthocillin analogues for use in the treatment of neurodegenerative diseases, to some of said analogues, as well as to methods for obtaining them and pharmaceutical composition comprising them. The invention al